The effect of snakehead fish extract supplementation to first-line eradication regimen on macrophage migration inhibitory factor (MIF) expression in rats induced by *Helicobacter pylori* infection

OK Yulizal¹, Aznan Lelo², Syafruddin Ilyas³, Raden Lia Kusumawati⁴

¹Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
²Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
³Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Medan, Indonesia
⁴Department of Microbiology, Faculty of Medicine, H. Adam Malik General Hospital, Universitas Sumatera Utara, Medan, Indonesia

ABSTRACT

**Objective:** This work was organized to assess macrophage migration inhibitory factor (MIF) expression in snakehead fish extract supplementation to first-line eradication regimen in rats induced by *Helicobacter pylori* infection.

**Materials and methods:** A total of 28 manly rats were haphazardly isolated equally into four groups. Group-1 was the control negative, and groups-2–4 were *H. pylori*-infected groups. Group-2 was the control positive. Groups-3 and 4 were treated with first-line eradication regimen and first-line eradication regimen supplemented with snakehead fish extract, respectively. Immunoreactive scores (IRS) of MIF expression and eradication testing procedure were carried out. The comparison and difference between groups were analyzed by Kruskal–Wallis and post hoc Mann–Whitney U-test. A value of $p < 0.05$ was considered to be a limit of significance.

**Results:** The average IRS of MIF expression in group-2 was the highest among other groups ($p < 0.05$). Group-4 (supplemented by snakehead fish extract) had a lower median value IRS of MIF expression compared to group-3 [1.0 (0.0–2.0) vs. 3.5 (2.0–6.0), $p = 0.004$].

**Conclusion:** MIF expression was higher in rats induced by *H. pylori* infection. Snakehead fish extract supplementation to first-line eradication regimen significantly reduces more MIF expression compared to a single administration of first-line eradication regimen in rats induced by *H. pylori* infection.

Introduction

It is estimated currently that most of the world’s populace stomach colonized and contaminated by *Helicobacter pylori* [1]. *H. pylori* is a microaerophilic microorganism that is pathologically found within the gastric mucosa or attached to the gastric epithelium. As one of the most prevalent human pathogens, *H. pylori* is clinically linked with gastritis, gastritis ulcer, and gastric malignancy, especially to developing countries, at an average prevalence of around 80% [2].

Virulence factors, inflammatory response, releasing of chemokines, cytokines, and reactive oxygen species (ROS) due to *H. pylori* infection play a role in the formation of gastric pathological lesions above [3]. Virulence factors, as destructive components, including cytotoxin-associated gene A (CagA), vacuolating cytotoxin A (VacA), lipopolysaccharides, ureases, and flagella induce the encourage of proinflammatory cytokines within the gastric mucosal to complicated long-term immunoinflammatory responses in producing cytotoxic molecules that lead to gastric mucosal damage and heading to gastric malignancy [4]. *H. pylori* generates an innate immune response that implicates many types of innate immune system constituents. This innate immune response proceeds inflammation to gastric
mucosa and causes an inflow of neutrophils and distinct immune cells through the liberation of various cytokines and chemokines [5].

Macrophage migration inhibitory factor (MIF) constitutes notable cytokine to regulate immune reaction, inflammatory progression, and immune system-mediated diseases such as autoimmune diabetes mellitus, asthma, rheumatoid arthritis, atherosclerosis, and several diseases in the gastrointestinal system [6]. MIF enhances the inflammatory reaction by provoking the expression of other proinflammatory cytokines, such as interleukin-1 beta (IL-1β), tumor necrosis factor-α (TNF-α), IL-8, IL-6, and interferon-gamma (IFN-γ) through attachment to its natural receptor, cluster-differentiated 74 (CD74) [7].

It was stated in a study that the increase of MIF expression in the gastrointestinal system is closely related to the occurrence of gastritis, gastritis ulcer, gastric malignancy, ulcerative colitis, and colon cancer [8]. MIF is generated by stress, endotoxins, exotoxins, and several bacterial infections, including H. pylori infection [9]. A study in Turkey found that MIF levels increased during H. pylori infection and decreased significantly after eradication with a first-line eradication regimen [10].

Nowadays, proton-pump inhibitor (PPI)-based triple therapy is a first-line regimen in the eradication of H. pylori worldwide [11]. The effectiveness of first-line eradication regimen is felt to be less than optimal regarding the problem of patient’s immune, patient compliance, nutritional status, and antibacterial resistance issue in certain regions [12]. Besides, the long-term inflammation caused by H. pylori infection also becomes the focus of attention [13]. Therefore, the efforts in finding agents or drugs that come from nature as a supplementation to first-line eradication regimen continue to be pursued to overcome those problems.

Snakehead fish, known by several names such as Channa striata, Ophicephalus striatus, Chevron snakehead, and Stripped snakehead, is a medicinal fish that is widely consumed by people in Asia-Pacific, especially Indonesia. Snakehead fish in Indonesian called as “ikan gabus,” has been known to have properties in accelerating the recovery process after suffering an illness, healing wounds in post-surgery condition and to mother after childbirth, reducing pain, antipyretic, treatment of several skin disorders, and anti-inflammatory [14].

Several studies have documented the benefits of snakehead fish extract in medicine. The usability of snakehead fish extract as an anti-inflammatory has been investigated by Dwijayanti et al. [15]. Other researchers have found the potential effect of snakehead fish extract as an antibacterial and antifungal in a few in vitro studies, such as those studied by Kumar et al. [16], Dhanaraj et al. [17], Zulaikha et al. [18], and Andini et al. [19]. Furthermore, a work noted that the supplementation of snakehead fish extract capsules to antituberculosis drugs in pulmonary tuberculosis patients decreases the proinflammatory cytokine levels significantly [20].

Concerning to the medicinal properties of snakehead fish extract, we were interested to examine its beneficial effect, supplemented to first-line eradication regimen, in lowering gastric inflammatory by investigating MIF expression in rats induced by H. pylori infection. Based on the literature research, there are still very few studies published regarding the involvement of animal extract in the management of H. pylori infection. This can be the primary study to examine the medicinal effect of snakehead fish extract supplementation to the first-line H. pylori eradication regimen addressing in the lowering of MIF expression. The existence of this study is expected to be able to contribute to science, knowledge, and complement previous research associated with the management of H. pylori infection.

The purpose of this work was to assess MIF expression in snakehead fish extract supplementation to H. pylori first-line eradication regimen in rats induced by H. pylori infection.

Materials and Methods

Ethical approval

Before this work, we obtain ethical feasibility from the Animal Research Ethics Committee, Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Medan, Indonesia, with number of letter: 0448/KEPH-FMIPA/2019 to perform all trials and procedures of this work.

Experimental animals and study design

We bought and used 28 male albino rats, Rattus norvegicus, as experimental animals in Biomedical Research Unit, West Nusa Tenggara Province General Hospital from October 2019 to December 2019. The animal in this work had average body weight and age of 294 gm and 8–12 weeks, respectively. The selected criteria included health, active movement, and good appetite. We excluded subjects in sickness condition or die during this work. They were located in cages in a laboratory environment at room temperature of around 26°C under 12-h cycles in a day, free access to water and standard food. The work began by adapting rats for 7 days in a laboratory. This work applied a post-test only with a control group design, and the determination of samples was done by simple random sampling.
Provision of bacteria

Gastric biopsy specimens of duodenal ulcer patients, which were stored and cultured in Microbiology Laboratory, Biomedical Research Unit, West Nusa Tenggara Province General Hospital, were used to acquire *H. pylori* isolates. Furthermore, *H. pylori* from this human isolate was cultured using Tryptic Soy Agar (TSA) (Cat. No. CM0131B, Oxoid™, Thermo Scientific™, Hampshire, UK) added with 10% fresh sheep blood, Dent Supplement (Oxoid™, Thermo Scientific™, Hampshire, UK), and Vitox Supplement (Oxoid™, Thermo Scientific™, Hampshire, UK). Under microaerophilic atmospheric condition with a concentration of 5% O₂, 10% CO₂, and 85% N₂, the incubation process was performed in a CO₂ incubator for 72 h at 37°C. Later on, we provide *H. pylori* from formed colonies based on colony appearance, equipped with microscopic examination by Gram stain and biochemical analysis. The rats in groups-2, 3, and 4 were inoculated with *H. pylori* suspension containing 5 × 10⁵–5 × 10¹⁰ colony-forming unit/ml (CFU/ml) in 0.9% NaCl at 1 ml/rat.

Snakehead fish extract and first-line eradication regimen

Snakehead fish extract was a factory ready-made product by name Channa® capsules (PT Mega Medica Pharmaceuticals, Jakarta, Indonesia). The product packed up in capsules, where each 500 mg of capsule comprises pure snakehead fish extract powder. The composition of chemical active substance of Channa® has been analyzed at the Faculty of Pharmacy, Muhammadiyah University, Surakarta, Central Java, Indonesia. Snakehead fish extract, which was diluted in 0.5% (w/v) carboxymethyl cellulose (0.5% CMC), was given orally by intragastric gavage to rats in groups-3 and 4 at a dose of 300 mg/kgBW (kg body weight), 1 ml/rat daily. We determined a dose of 300 mg/kgBW as a treatment dose based on the previous studies [21,22]. First-line eradication regimen refers to PPI-based triple therapy composed of amoxicillin, clarithromycin, and omeprazole (PT Indoefarma, Jakarta, Indonesia) in aqueous solution in a dose of 50, 25, and 20 mg/kgBW, respectively, diluted in 0.5% CMC [23]. All agents and drugs in this study were purchased privately from a commercial drug store.

Experimental procedure

After passing a week of adaptation period, all rats were then distributed randomly into four groups of seven rats each: group-1 as control negative (without *H. pylori* inoculation), group-2 as control positive (with *H. pylori* inoculation), group-3 as *H. pylori* inoculation + first-line eradication regimen group (aqueous solution of amoxicillin 50 mg/kgBW + clarithromycin 25 mg/kgBW + omeprazole 20 mg/kgBW), and group-4 as supplementation group, *H. pylori* inoculation + first-line eradication regimen (aqueous solution of amoxicillin 50 mg/kgBW + clarithromycin 25 mg/kgBW + omeprazole 20 mg/kgBW) + snakehead fish extract with a dosage of 300 mg/kgBW.

Rats in groups-2, 3, and 4 were supplemented with an aqueous solution of streptomycin (PT Indoefarma, Jakarta, Indonesia) from tap drinking water (5 mg/ml) for 72-h before the inoculation of *H. pylori*, whereas animals in group-1 were normally given drinking water. All rats on the following day were not given food for a day.

The rats in groups-2, 3, and 4 were then inoculated with the aqueous suspension of *H. pylori* (1 ml to each animal) orally to gaster through gavage for two times per day at an interim of 4 h for 3 successive days, whereas group-1 was treated with a solution of 0.9% (w/v) natrium chloride (0.9% NaCl) at 1 ml to each animal orally to gaster through gavage for two times per day at an interim of 4 h for 3 successive days. All rats in groups-2, 3, and 4 were given oral omeprazole (PT Indoefarma, Jakarta, Indonesia) at 1 ml/rat once a day by intragastric gavage with a dose of 400 μmol/kgBW dissolved in 0.5% CMC, 3 h before the first *H. pylori* inoculation and during the following 6 days. Similar to the procedure in three previous groups, group-1 was given 0.5% CMC suspension instead of omeprazole. Two weeks after the last day of *H. pylori* inoculation, all rats were not given any food for 12 h before the next procedure. On the next morning, a rat from each group was randomly selected to evaluate the success of creating *H. pylori* infection. They were sacrificed under toxic dose of diethyl ether. Furthermore, a selected rat from all groups was performed surgical procedure. With regard to detect *H. pylori* in gastric tissue, gastric antrum area about 4 mm² was cut and take on an urease test (Pronto Dry®, Gastrex, France). We found the positive urease test results in rats that represented inoculation groups from this procedure.

On the following days, the remaining rats from each group were then administered with drugs and/or extracts for 7 consecutive days through intragastric gavage. Groups-1 and 2 were given 0.5% CMC suspension once a day. Meanwhile, group-3 was given first-line eradication regimen at 1 ml/rat once a day, group-4 was given first-line eradication regimen and snakehead fish extract at an interval of 6 h once a day. Four weeks after this procedure, all rats were then sacrificed under a toxic dose of diethyl ether. The laparotomy procedure was done to take a small fragment of gastric antrum region to perform the rapid urease test as the previous description. It was noted that all rats in the infected groups were successfully infected with *H. pylori*. Later on, the remaining gastric antrum portion was provided for immunohistochemistry (IHC) examination and eradication testing procedure.
**Immunohistochemistry procedure and analysis**

Gastric mucosal tissue from the antrum region was taken and fixed with 10% buffered neutral formaline solution with pH 7.4 for 24 h. Afterward, tissue processing and embedding were settled on the paraffin block. The paraffin block was cut into a thickness of 5 µm and located on the slides before staining. A part of the 5-µm paraffin blocks was deparaffinized, rehydrated with 96%, 90%, and 80% alcohol, and warmed with a buffer citrate pH 6.0 for 20 min in a microwave. The samples were then dropped with secondary antibody, incubated for 20 min, given diaminobenzidine, and counterstained with hematoxylin.

The examination of MIF expression used immunoreactive score (IRS), which was the outcome of multiplication between the percentage score of immunoreactive cells and color intensity scores on immunoreactive cells at IHC staining. The percentages of immunoreactive cells are grouped as follows: score 0 determined as no staining cells found, score 1 determined as staining cells below 10%, score 2 determined as staining cells between 10% and 50%, score 3 determined as staining cells between 51% and 80%, and score 4 determined as staining cells above 80%. Color intensity is characterized by the appearance of brown cells, whereas negative staining results are marked with a paler color. Color intensity is grouped as follows: score 0 determined colorless, score 1 determined as weak intensity, score 2 determined as moderate intensity, and score 3 determined as strong intensity. The MIF expression is classified into four groups, namely, negative (IRS 0–1), weak (IRS 2–3), moderate (IRS 4–8), and strong (IRS 9–12) [24]. The observation of MIF expression was carried out using Olympus® CX22 LED binocular light microscope with a magnification of 100× and 400× equipped with Vivo® 9 camera. Microscopic examination was conducted blindly by two pathologists.

**Eradication testing procedure**

A piece section of gastric mucosal from the antrum area about 4 mm² was put into normal saline solution, then crushed, and homogenized. Furthermore, the dilutions of 1/10, 1/100, and 1/1000 were made, and each 1 ml of those dilutions was taken to be spread on the surface of plates containing TSA culture media (Cat. No. CM0131B, Oxoid™, Thermo Scientific™, Hampshire, UK) added with 10% fresh sheep blood. The plates were then incubated in a CO₂ incubator at 37°C in microaerophilic conditions for 72 h. We identified *H. pylori* colonies morphologically and biochemically. The number of colonies per plate was calculated and expressed as CFU logs per hull wall. The calculation of formed colonies was done using a colony counter.

**Statistical analysis**

The normality of quantitative variable was decided by the Shapiro–Wilk test. A descriptive analysis was reported as mean ± standard deviation (SD) or median (minimum value–maximum value). The one-way analysis of variance (ANOVA) test was used to specify the differences between quantitative variables in normal distribution and Kruskal–Wallis test to specify the differences between quantitative variables in non-normal distribution with post hoc Mann–Whitney U-test. The SPSS software v.22 was applied to perform the calculation. A value of $p < 0.05$ was determined as a limit of significance.

**Results**

This work resulted in a positive urease test in all rats those inoculated by *H. pylori*. A microscopic assessment of MIF expression in gastric epithelial cells observed according to the changes in color intensity on IHC staining. Color intensity was represented by the appearance of brown cells, whereas negative staining results were marked with a paler color. The expression of MIF was stronger in *H. pylori* inoculation groups (group-2 to group-4) than the negative control group (group-1). This is shown in Figure 1.

The IRS of MIF expression was decided in accordance with the results of multiplication between the percentage score of immunoreactive cells with color intensity scores. The calculation results regarding this are shown in Table 1, which was statistically computed by Kruskal–Wallis test.

To find out the difference in average IRS of MIF expression between the groups, Mann–Whitney U-test was performed. The results of analysis are shown in Table 2.

Eradication testing procedure is an effort to assess the success of *H. pylori* eradication. The output of this assessment is shown in Figure 2 and Table 3.

In Figure 2 and Table 3, the growth of *H. pylori* was only seen in group-2, and no *H. pylori* growth was found in the other groups.

**Discussion**

Pretreatment with streptomycin and omeprazole to inhibit the growth of other bacteria and reduce gastric acidity respectively turned out to produce a positive rapid urease test in *H. pylori*-inoculated groups. This effort is in accordance with several previous studies [25,26]. *H. pylori* infection leads to long-term inflammation and produces gastric pathological lesions that clinically manifest as gastritis, peptic ulcer disease to gastric cancer. A
long-term inflammation is inseparable from the role of lymphokines such as MIF. MIF was derived from several immune cells such as granulocytes, T-cells, B-cells, dendritic cells, macrophages, and monocytes [27]. MIF regulates innate immunity system and adaptive immunity system. Releasing and increasing of MIF activity due to *H. pylori* infection will induce the activation of other proinflammatory cytokines comprising TNF-α, IL-1β, IFN-γ, IL-6, and IL-8 [28]. These cytotoxic mediators tend to recruit neutrophils, macrophages, and T-cells into gastric mucosa, which will cause long-term inflammation and various pathological lesions in the gastric mucosa [9]. The work noticed that the inoculation of *H. pylori* produced an increase of MIF expression, and this was associated with the enhancement density and growth of *H. pylori* in the eradication testing procedure as shown in group-2. We observed that, by performing an eradication testing procedure, there was no *H. pylori* growth in groups treated by first-line eradication regimen (groups 3 and 4) as well as the decrease of MIF expression in both groups.

![Figure 1. Representation of macrophage MIF expression in IHC staining (Magnification 100×).](image)

**Table 1.** Average IRS of MIF expression in each group.

| Groups    | Immunoreactive score | p value |
|-----------|----------------------|---------|
| Group-1   | 0.17 ± 0.41          | 0.000*  |
| Group-2   | 7.50 ± 1.64          |         |
| Group-3   | 4.00 ± 1.67          |         |
| Group-4   | 1.00 ± 0.63          |         |

Data were expressed as mean ± SD. Statistical test using Kruskal–Wallis. Number of subject per group 6. *p < 0.05.
In this study, it was encountered that the supplementation of snakehead fish extract to first-line eradication regimen significantly reduced the MIF expression more than the single administration of first-line eradication regimen (group-4 vs. group-3).

The first-line eradication regimen consists of omeprazole, amoxicillin, and clarithromycin. The presence of omeprazole reduces gastric acidity by reducing the pH gradient and producing chemotactic bias in *H. pylori* so that the performance of antibiotics is more optimal [29]. Amoxicillin with its intraluminal topical activity acts by inhibiting bacterial cell wall and membrane synthesis. The administration of a combination of omeprazole and amoxicillin elevates the ability of eradication because the reduction of gastric acidity level leads to the increment of amoxicillin concentration in the stomach beyond the minimum inhibitory concentration to *H. pylori* [3,11]. Clarithromycin, a macrolide antibiotic, works by binding to the 50s bacterial ribosome subunit to inhibit peptide translocation so that the transcription and translational process of *H. pylori* protein is disrupted. Combining clarithromycin with amoxicillin will increase the eradication rate by more than 70%.

| Group comparison | Immunoreactive score | p value |
|------------------|----------------------|---------|
| Group-1 vs. Group-2 | 0.0 (0.0–1.0) vs. 7.5 (6.0–9.0) | 0.002* |
| Group-1 vs. Group-3 | 0.0 (0.0–1.0) vs. 3.5 (2.0–6.0) | 0.003* |
| Group-1 vs. Group-4 | 0.0 (0.0–1.0) vs. 1.0 (0.0–2.0) | 0.026* |
| Group-2 vs. Group-3 | 7.5 (6.0–9.0) vs. 3.5 (2.0–6.0) | 0.012* |
| Group-2 vs. Group-4 | 7.5 (6.0–9.0) vs. 1.0 (0.0–2.0) | 0.003* |
| Group-3 vs. Group-4 | 3.5 (2.0–6.0) vs. 1.0 (0.0–2.0) | 0.004* |

Data were expressed as median (minimum–maximum). Statistical test using Mann–Whitney. Number of subject per group 6. *p < 0.05
In this study, it was noted that the single administration of a first-line eradication regimen resulted in complete eradication rate without the issue of antibacterial resistance. Therefore, the first-line eradication of *H. pylori* regimen can reduce MIF expression, and this finding is in accordance with a study from Kebapcilar et al. [10].

Snakehead fish extract has been known as a potential natural anti-inflammatory. Albumin, amino acids, fatty acids, and minerals contained in snakehead fish extract have therapeutic effects due to their anti-inflammatory, antioxidant, and even antibacterial properties [31]. Sulphydryl cluster (-SH) in albumin and minerals (zincum, cuprum, and ferrum) have antioxidant properties that act as ROS scavenger and cellular protection against oxidative stress, besides that thiol cluster in albumin was known as antibacterial in septicemia condition [32]. An *in vitro* study in Texas, United States, found that albumin can interrupt biofilm formation by inhibiting the bacterial quorum sensing [33]. Some previous *in vitro* study reported the antibacterial activity of some amino acids [34,35]. Amino acids such as lysine, arginine, aspartic, and glutamic acid also perform as antioxidant and anti-inflammatory synergistically with some fatty acids, such as linoleic, arachidonic, stearic, and oleic acid [36]. The generation of proinflammatory cytokines was disturbed by linoleic and arachidonic acids, while stearic and oleic acids serve by reducing the polymorphonuclear leukocyte activity and weakening the expression of endothelial leukocyte adhesion molecules, respectively [37].

This study highlighted that snakehead fish extract supplementation to first-line eradication regimen tends to have a profitable effect in reducing more MIF expression. This finding obviously showed a potential effect of first-line eradication regimen and snakehead fish extract mainly in *H. pylori* eradication and suppression of inflammatory event, respectively. This study is in line with several studies. A research reported significant decreases in proinflammatory cytokine levels after 12 weeks of supplementation of *C. striata* extract capsules into antituberculosis drugs in pulmonary tuberculosis patients [20]. Similarly, another study documented that there was an acceleration in the healing of pulmonary tuberculosis clinically in patients with pulmonary tuberculosis, who administered a combination of antituberculosis drugs and *C. striata* extract capsules [38].

We noticed some limitations that might be found in this study, including the unknown type of *H. pylori* strain and the use of snakehead fish extract without varying doses.

### Conclusion

We noted that MIF expression was higher in *H. pylori*-infected groups. The conclusion of this work exhibited that snakehead fish extract supplementation to first-line eradication regimen significantly reduces more MIF expression compared to the single administration of first-line eradication regimen in rats induced by *H. pylori* infection.

### Acknowledgment

The authors would like to thank the Head and staff of Microbiology Laboratory, Biomedical Research Unit, West Nusa Tenggara Province General Hospital, for their support to this research.

### Conflict of interest

The authors announce that they have no conflict of interest regarding creation and publication of this paper.

### Authors’ contribution

OKY designed and managed the study, did laboratory works, deciphered data, and drafted and wrote the paper. AL was involved in planning and basic checking of the paper. RLK involved in planning and basic checking of the paper. SI deciphered data, and drafted and wrote the paper. AL was involved in planning and basic checking of the paper. RLK involved in planning and basic checking of the paper.

### References

[1] Li J, Perez-Perez GL. *Helicobacter pylori* the latent human pathogen or an ancestral commensal organism. Front Microbiol 2018; 9:1–8; https://doi.org/10.3389/fmicb.2018.00609

[2] Quach DT, Vilachone RK, Van Vu K, Yamaoka Y, Sugano K, Mahachai V. *Helicobacter pylori* infection and related gastrointestinal diseases in southeast Asian countries: an expert opinion survey. Asian Pacific J Cancer Prev 2018; 19(12):3565–9; https://doi.org/10.31557/APJCP2018.19.12.3565

Table 3. The growth of *H. pylori* in eradication testing procedure.

| Groups | n | Colony-forming unit | Successful rate (%) |
|--------|---|----------------------|---------------------|
| Group-1 | 6 | not detected | – |
| Group-2 | 6 | 1,600 (1,600.00–4,800.00) | 0/6 (0%) |
| Group-3 | 6 | not detected | 6/6 (100%) |
| Group-4 | 6 | not detected | 6/6 (100%) |

Data were expressed as median (minimum–maximum).
[3] De Brito BB, Da Silva FAE, Soares AS, Pereira VA, Cordeiro Santos ML, Sampaio MM, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol 2019; 25(37):5578–89; https://doi.org/10.3748/wjg.v25.i37.5578

[4] Park JY, Forman D, Wasikto LA, Yamaoka Y, Crabtree JE. Epidemiology of Helicobacter pylori and CagA-positive infections and global variations in gastric cancer. Toxins 2018; 10(163):1–20; https://www.doij.org/10.3390/toxins10040163

[5] Pacheco-Fernández T, Juárez-Avelar I, Illescas O, Terrazas LI, Hernández-Pando R, Pérez-Plascencia C, et al. Macrophage migration inhibitory factor promotes the interaction between the tumor, macrophages, and T cells to regulate the progression of chemically induced colitis-associated colorectal cancer. Mediators Inflamm 2019; 2019:1–16; https://doi.org/10.1155/2019/2056085

[6] Schindler L, Dickerhof N, Hampton MB, Bernhagen J. Post-translational regulation of macrophage migration inhibitory factor: basis for functional fine-tuning. Redox Biol 2018; 15:135–42; https://doi.org/10.1016/j.redox.2017.11.028

[7] Zheng YX, Yang M, Rong TT, Yuan XL, Ma YH, Wang ZH, et al. CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer. World J Gastroenterol 2012; 18(18):2253–61; https://doi.org/10.3748/wjg.v18.i18.2253

[8] Xia HX, Yang Y, Chu KM, Gu Q, Zhang YY, He H, et al. Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer. Cancer 2009; 115(23):5441–9; https://doi.org/10.1002/cncr.24609

[9] Yu X, Zhang Q, Yang X, Yang W, Dai F, Qian Z, et al. Expression of macrophage migration-inhibitory factor in duodenal ulcer and its relation to Helicobacter pylori infection. Genet Mol Res 2015; 14(4):13860–7; https://doi.org/10.4238/2015.October.29.6

[10] Kebapcilar L, Bilgir O, Cetinkaya E, Akyol M, Bilgir F, Bozkaya G. Macrophage migration inhibitory factor as a diagnostic and prognostic biomarker. Mediators Inflamm 2015; 2015:1–6; https://doi.org/10.1155/2015/849647

[11] Debraekeleer A, Remaut H. Future perspective for potential Helicobacter pylori eradication therapies. Future Microbiol 2018; 13(6):671–87; https://doi.org/10.2217/fmb-2017-0115

[12] Khien V Van, Thang DM, Hai TM, Duat NQ, Khanh PH, Ha DT, et al. Management of antibiotic-resistant Helicobacter pylori infection: perspectives from Vietnam. Gut Liver 2019; 13(5):483–97; https://doi.org/10.5056/jgl180237

[13] Sintara K, Thong-Ngam D, Patumraj S, Klaikeaw N, Chatsuwan ML, Sampaio MM, et al. Management of antibiotic-resistant Helicobacter pylori – induced gastric ulcers in rats. J Tradit Complement Med 2018; 7:1–9; https://doi.org/10.1016/j.jtcme.2018.05.001

[14] Jeung J, Patel R, Vila L, Wakefield D, Liu C. Quantification of HER2/neu expression in primary gastrointestinal adenocarcinomas using conventional light microscopy and quantitative image analysis. Arch Pathol Lab Med 2012; 136(6):610–7; https://doi.org/10.1093/aj worship.2015.06.076

[15] Muhtadi, Annissa YN, Suhendri A, Sutrisna E. Hypoglycemic effect of Zingiber zerumbet ethanolic extracts and Channa striata powder in alloxan-induced diabetic rats. J Nutraceuticals Herbal Med 2018; 1(1):9–15.

[16] Bhattacharja SK, Yan YL, Lee CK, Kuean CH, Candasamy M, Liew YK, et al. Protective activity of geraniol against acetic acid and Helicobacter pylori – induced gastric ulcers in rats. J Tradit Complement Med 2018; 7:1–9; https://doi.org/10.1016/j.jtcme.2018.05.001

[17] Yu L, Li Y, Sun H, Zhen X, Qiao C, Tian S, et al. Current developments of macrophage migration inhibitory factor (MIF) inhibitors. Drug Discov Today 2013; 18(11–12):592–600; https://doi.org/10.1016/j.drudis.2012.12.013

[18] Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3(10):791–800; https://doi.org/10.1038/nri1200

[19] Mori H, Suzuki H. Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium–competitive acid blocker. J Neurogastroenterol Motil 2019; 25(1):6–14; https://doi.org/10.5056/jnm18139

[20] Malfettheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection: the Maastricht V/Florence consensus report. Gut 2017; 66(1):6–30; http://dx.doi.org/10.1136/gutjnl-2016-312208

[21] Haniffa MAK, Scheila P, Kovita K, Jais AMM. Salutary value of haruan, the striped snakehead Channa striata – a review. Asian Pac J Trop Biomed 2014; 4(S1):S8–15; https://doi.org/10.1016/j.apjtb.2014c1015

[22] Hirayada D, Faizah A, Prasetyo EN, Jaddid N, Abdullagan N. Antioxidant capacity of Snakehead fish extract (Channa striata) at different shelf life and temperatures. J Phys Conf Ser 2018; 1028(1):1–5; https://doi.org/10.1088/1742-6596/1028/1/012021

[23] Smith AC, Rice A, Sutton B, Gabriella R, Wessel AK, Whiteley M, et al. Alumunium inhibits Pseudomonas aeruginosa quorum sensing and alters polymicrobial interactions. Infect Immun 2017; 85(9):1–12; https://doi.org/10.1128/aii.00116-17

[24] Awada AS, Alafeefy AM, Almasyar FA, El-Megly RM, Zain ME, Alqausomi SI. Novel essential amino acid-sulfanilamide hybrid as...
safe anti-ulcerogenic agent with anti-*Helicobacter pylori* activity. Saudi Pharm J 2017; 25(7):967–71; https://doi.org/10.1016/j.jsps.2017.02.012

[35] Siebert A, Wysoka M, Krawczyk B, Cholewiński G, Rachoń J. Synthesis and antimicrobial activity of amino acid and peptide derivatives of mycophenolic acid. Eur J Med Chem 2018; 143:646–55; https://doi.org/10.1016/j.ejmech.2017.11.094

[36] Galla NR, Karakala B, Akula S, Pamidighantam PR. Physico-chemical, amino acid composition, functional and antioxidant properties of roe protein concentrates obtained from *Channa striatus* and *Lates calcarifer*. Food Chem 2012; 132(3):1171–6; https://doi.org/10.1016/j.foodchem.2011.11.055

[37] Abedi S, Ehtesham FF, Khairi Hus M, Ahmad Z, Manan Mat A. Effects of *Haruan* (*Channa striatus*) based cream on acute inflammation in Croton oil induced mice ear edema model. Res J Biol Sci 2012; 7(4):181–7; http://dx.doi.org/10.3923/rjbsci.2012.181.187

[38] Ma’rufi I, Ali K, Sedemen IA, Purwanto P, Khoiri A. *Channa striata* (*Ikan Gabus*) extract and the acceleration of tuberculosis treatment: a true experimental study. Interdiscip Perspect Infect Dis 2019; 2019:1–7; https://doi.org/10.1155/2019/8013959